Lipophilicity, conventionally expressed as the logarithm of the partition coefficient between n-octanol and water, log P o/w, is one of the most influential parameters in early drug discovery. It governs how readily a molecule crosses cell membranes, binds to plasma proteins, and distributes through tissues, thereby shaping absorption, distribution, metabolism, excretion, and toxicity. According to Lipinski’s rule of five, orally administered small-molecule candidates should ideally fall between 0 and 5 on this scale. Values above that window are frequently associated with poor aqueous solubility, excessive plasma protein binding, tissue accumulation, receptor promiscuity, and elevated in vivo toxicity, while insufficient lipophilicity undermines the same pharmacokinetic machinery from the opposite direction.

Measuring that property experimentally has traditionally relied on the OECD shake flask method, a liquid-liquid extraction procedure that is slow, material-hungry, and unforgiving of impure samples. Reversed-phase HPLC has emerged as a faster and more economical alternative, requiring only tiny amounts of compound and tolerating impurities. Because different stationary phases, from conventional C18 silica to polymer-based supports, present distinct hydrophobic surfaces and residual silanol populations, running a candidate across several columns yields a richer picture of lipophilic behavior than any single system can provide.

In the new work, the researchers dissolved each of the thirty-one cis- and trans-styrylbenzoxazolone derivatives and injected them onto three different C18 columns operated with either methanol-water or acetonitrile-water mobile phases, generating five distinct chromatographic systems. Isocratic elution ran from 95 percent down to 60 percent organic modifier at 0.75 ml/min and 35 °C, with a diode array detector recording at 254, 274, 292, and 305 nm. Because direct measurement in pure water would demand prohibitively long run times, the team measured retention factors at each eluent composition and extrapolated the linear or quadratic relationship between log k and the organic fraction back to zero organic modifier, yielding the chromatographic hydrophobicity index log kw.

Choosing between the linear Snyder-Soczewinski model and its quadratic extension is not trivial, since the quadratic coefficients proved vanishingly small across all systems. The authors therefore applied Mandel’s test, the IUPAC-recommended Fisher F-test comparison of residual variances, to decide which regression form best described each analyte. After extending the mobile phase interval with additional 65 and 75 percent compositions, the test confirmed linear behavior for only a handful of compound-system pairs, including S55-Z in system A, S67-Z in system B, S44-E in system C, and S48-E in system D. Notably, no derivative required a linear model on system E, whose endcapped stationary phase suppresses unwanted secondary interactions and treats all the stilbenes uniformly.

The solvent itself left a clear imprint on the results. Methanol, a protonic solvent capable of hydrogen bonding, strengthens interactions between analyte and the hydrophobic C18 chains, prolonging retention, whereas aprotic, low-polarity acetonitrile competes more effectively in the mobile phase and elutes compounds faster. Accordingly, log kw values were consistently higher in the three methanol-water systems than in their acetonitrile counterparts. System C, built on a polymer-based matrix with wide 300 Å pores, showed the weakest retention, since large pores reduce diffusional obstruction and ease desorption, and the polymeric backbone changes the interaction mechanism altogether. System D, also polymeric and wide-pored, similarly produced the lowest retention values among the acetonitrile systems.

Molecular geometry mattered as well. In reversed-phase HPLC, retention mirrors the way a molecule threads itself between nonpolar stationary phase chains, a process favored by planar, elongated structures and nonpolar fragments. The trans, or E, isomers, being more extended than their cis counterparts, were expected to retain more strongly, and indeed every E-isomer outperformed its Z-partner on system A. Only scattered inversions appeared on the other systems, and two isomer pairs, S61-Z/S62-E on system D and S77-Z/S78-E on system E, converged to identical extrapolated log kw values despite different retention profiles across the mobile phase compositions.

On the computational side, the team used SwissADME to gather predictions from five algorithms: XLOGP3, an atomistic method with corrective factors and a knowledge-based library; WLOGP, a purely atomistic fragmental approach; MLOGP, a topological model built on thirteen molecular descriptors; SILICOS-IT, a hybrid of twenty-seven fragments and seven topological descriptors; and iLOGP, a physics-based method deriving free solvation energies in octanol and water through a Generalized-Born and surface area model. Their arithmetic mean forms the consensus clog P. The consensus values ranged narrowly from 3.10 to 3.24, placing every derivative comfortably within the Lipinski window. Compounds bearing three methoxy groups on ring A were the most polar, while those with a single methoxy group were the most lipophilic, and most E-isomers edged out their Z-analogues, with the largest isomer gap appearing at position 7 of the styryl residue.

Correlating experiment with theory revealed a decisive pattern. The methanol-water systems A, C, and E produced statistically significant agreement between clog P and chromatographic lipophilicity at p < .05, while the acetonitrile systems ranged from moderate (system B, p ≈ .05) to poor (system D, p > .05). The strongest correspondences appeared on the silica-based columns with methanol eluents, marking those configurations as the most reliable predictors of lipophilicity for this compound family, and singling out the polymer-based, wide-pore system D as the least suitable for these analytes.

Chemometrics then consolidated the picture. Hierarchical clustering analysis, visualized as a dendrogram built from a bottom-up merging algorithm and validated with the Sneath-Sokal dissimilarity index, split the compounds into two main clusters that loosely tracked the position of the styryl fragment on ring B. All 3,5-dimethoxy derivatives fell into cluster I, whereas the 3,4-dimethoxy analogues, with one exception, grouped into cluster II, which also harbored most of the Z-isomers and the lower-lipophilicity members of the set. Principal component analysis, using the Kaiser eigenvalue criterion and a statistically validated loading threshold based on p-values rather than arbitrary cut-offs, extracted two components explaining 41.98 and 23.69 percent of total variance. The first component behaved as a silica factor dominated by systems A, B, and E, while the second, shaped by the wide-pored polymeric systems C and D, acted as a polymeric factor. The score biplot confirmed the clustering and flagged S44-E and S74-E as the most strongly retained outliers across all five systems. Together, the chromatographic, computational, and chemometric results deliver a robust framework for steering future ADME-oriented optimization of these anticancer candidates.

Subject of Research: Lipophilicity characterization of novel combretastatin A-4 stilbene derivatives by reversed-phase HPLC and computational prediction

Article Title: Investigation of lipophilicity of new stilbene derivatives with chromatographic and computational approaches

Article References: Georgieva, S., Voyslavov, T., Chanev, C., & Petrov, O. (2026). Investigation of lipophilicity of new stilbene derivatives with chromatographic and computational approaches. Pharmacia, 73, Article e200443. https://doi.org/10.3897/pharmacia.73.e200443

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e200443

Keywords: lipophilicity, combretastatin A-4, stilbene derivatives, reversed-phase HPLC, log P, benzoxazolone, chemometrics, principal component analysis, hierarchical clustering, ADME, drug discovery, SwissADME

The urgency behind this work is difficult to overstate. The World Health Organization has warned that the world is effectively running out of antibiotics, listing the surge in antimicrobial resistance among the top ten threats to global public health. Multidrug-resistant bacteria, defined as those resistant in vitro to at least one agent in three or more antimicrobial categories, are emerging so quickly that existing drugs are losing their clinical value. Against that backdrop, the discovery of entirely new chemical scaffolds with measurable antibacterial activity and acceptable predicted safety is a notable step forward.

To measure activity, the researchers turned to a resazurin-based microdilution assay, a sensitive colorimetric technique performed in 96-well plates. Resazurin is a blue dye that living bacteria convert to a pink, reduced form as they metabolize; if a well stays blue after incubation, the bacteria in it have been inhibited. Each of the nine derivatives was serially diluted across the plate, and minimum inhibitory concentrations (MICs) were recorded alongside minimum bactericidal concentrations (MBCs), which capture the concentration needed to kill rather than merely stall the bacteria. The assay itself was validated against the standard antibiotic gentamicin, with results matching Clinical Laboratory Standards Institute and EUCAST reference values.

The headline result came from derivative 6, which achieved an MIC of just 0.0048 mg/mL against S. typhimurium—the lowest value in the entire series and, notably, lower than the MIC of gentamicin against the same organism. All nine derivatives showed broad-spectrum activity in the range of 0.0048 to 0.620 mg/mL, and derivatives 1, 4, 6, 8, and 9 were active against both Gram-negative species such as Escherichia coli, Salmonella typhimurium, and Klebsiella aerogenes and Gram-positive organisms including Bacillus cereus and Enterococcus faecalis. Statistical analysis using geometric means confirmed derivative 6 as the most active synthesized compound, followed by derivative 4, while derivative 7 ranked as the weakest.

One intriguing pattern emerged from the structure–activity data: potency did not track neatly with substituent chemistry. Derivatives sharing the same benzyl substituent at the R2 position, for example, varied widely in efficacy, and compounds with nearly identical R1 and R2 groups differed in activity. The authors attribute this to structural differences interacting with variations in bacterial cell wall architecture and pathogen-specific resistance mechanisms. Across all compound–organism pairs, the MBC was roughly five times the MIC, indicating that the molecules are primarily bacteriostatic at inhibitory concentrations and require a modest dose increase to deliver a killing blow.

To probe how these molecules might work at the molecular level, the team performed molecular docking against peptidoglycan glycosyltransferase, an enzyme central to bacterial cell wall assembly. Peptidoglycan forms the rigid backbone of the bacterial cell wall, and glycosyltransferase domains within penicillin-binding proteins polymerize glycan chains from lipid-linked precursors. Blocking this process causes osmotic instability and, ultimately, cell lysis—a mechanistically attractive target that many successful antibiotics already exploit. The docking protocol was validated by redocking the crystal structure’s native ligand, which reproduced the original binding pose and its key hydrogen bonds with residues including Glu83, Ser116, and Gln121.

When the synthetic derivatives were docked, derivative 6 again stood out, achieving a binding energy of −6.958 kcal/mol, the strongest among the series. Its benzene and pyridine rings, along with the indole heterocycle, packed into the binding pocket via hydrophobic interactions with Lys62, Tyr65, and Leu159, supplemented by a π–cation contact with Lys62 and π–π stacking with Tyr65. The nitrogen and oxygen atoms of the oxazepine ring are thought to facilitate hydrogen bonding within glycosyltransferase active sites, while related indole compounds have been shown to disrupt membrane potential, deplete ATP pools, interfere with exopolysaccharide production, and suppress biofilm formation—multiple complementary mechanisms wrapped into a single scaffold.

Potency means little if a drug candidate poisons the patient, so the team deployed a comprehensive in silico safety workup. The CLC-Pred platform screened all nine derivatives for cytotoxicity across a panel of 198 human cell lines, and none exceeded the 0.5 probability-of-activity threshold conventionally associated with likely toxicity. Mean activity probabilities ranged only from 0.219 to 0.253, and normal cell lines such as skin and lung fibroblasts showed significantly lower predicted activity (Pa = 0.151) than tumor-derived lines (Pa = 0.249), hinting at a selectivity margin in favor of healthy tissue. Quantitative structure–activity/toxicity modeling predicted every derivative to be inactive for cytotoxicity, mutagenicity, and carcinogenicity.

Pharmacokinetic predictions proved equally encouraging. SwissADME analysis showed that most derivatives are highly absorbed in the gastrointestinal tract, and derivative 5 emerged as the standout from a drug-likeness perspective, with a Log P of 2.50—comfortably within the lipophilicity window defined by Lipinski’s Rule of Five—and zero violations. Derivative 5 was therefore flagged as the safest, most balanced lead for future structural optimization, while derivative 6 remains the potency champion. Compared with gentamicin, derivative 6 still required roughly 3.7-fold higher concentrations by geometric-mean MIC, so there is room for medicinal chemists to close the gap.

As with all early-stage discovery work, the caveats matter: these safety and mechanistic conclusions rest on computational prediction and in vitro assays, and the authors emphasize that in vitro cytotoxicity validation must confirm the predicted margins before any move toward preclinical development. Still, the study delivers exactly what the antibiotic pipeline desperately needs—a validated new chemical class with demonstrable broad-spectrum activity, a plausible cell-wall-targeting mechanism, and a computational safety profile clean enough to justify further investment. Whether derivative 6 or its optimized descendants eventually reach the clinic, the oxazepino–indole hybrid scaffold has now earned its place on the list of structures worth watching in the fight against drug-resistant bacteria.

Subject of Research: Antibacterial activity, molecular docking, and in silico safety profiling of novel indole-fused oxazepine derivatives

Article Title: Antibacterial activity, molecular docking, and in silico safety profiling of novel 3,10-dihydro- 2H -1,3-oxazepino[7,6- b ]indole derivatives

Article References: Sammor, M. S., Abu-Halaweh, M. M., Al Abrouni, K., Chandrasekaran, B., Dahadha, A., & Khazaleh, N. (2026). Antibacterial activity, molecular docking, and in silico safety profiling of novel 3,10-dihydro-2H-1,3-oxazepino[7,6-b]indole derivatives. Pharmacia, 73, Article e199777. https://doi.org/10.3897/pharmacia.73.e199777

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e199777

Keywords: antibiotic resistance, indole, oxazepine, minimum inhibitory concentration, molecular docking, peptidoglycan glycosyltransferase, QSAR, SwissADME, drug-likeness, Salmonella typhimurium, cytotoxicity prediction, drug discovery

The therapeutic logic behind the work rests on the deep biological overlap between inflammatory and allergic disease. COX-2 catalyzes the conversion of arachidonic acid into prostaglandins when tissues become inflamed, driving pain, fever, and swelling, while histamine acting through H1 receptors triggers vasodilation, smooth muscle contraction, and itching. In conditions such as allergic rhinitis with sinus inflammation or chronic urticaria with an inflammatory component, both pathways fire at once. A compound that engages both could, in principle, deliver synergistic benefit, lower the effective dose of each mechanism, reduce drug-drug interactions, and improve patient adherence. The authors point to rupatadine, which combines H1 antagonism with platelet-activating factor inhibition, as an existing proof that multi-target antihistamines can succeed clinically.

The benzimidazole scaffold was a deliberate choice. This fused benzene-imidazole ring system structurally resembles the purine bases of DNA, which helps it form favorable contacts with a wide range of biological targets. Benzimidazole drugs already span an impressive pharmacological range, from anti-inflammatory and antimicrobial to antiviral, anticancer, and antiparasitic activity. Previous studies have shown that suitably substituted benzimidazoles can act as selective COX-2 inhibitors with improved gastrointestinal safety compared with traditional NSAIDs; one reported series of methyl sulfonyl-substituted analogues achieved sub-micromolar inhibitory potency in enzyme assays. What had not been done before, according to the authors, was a systematic dual-target evaluation of a single benzimidazole series against both COX-2 and the H1 receptor.

The design itself was methodical. All eleven compounds, labeled SP1 through SP11, share a 2-phenyl-1H-benzimidazole core connected through an acetamide linker at the N-1 position to a variable substituent. That substituent was varied deliberately across chemical space: aromatic groups such as aniline and resorcinol, aldehyde-bearing moieties including salicylaldehyde and isovanillin, carboxylic acids ranging from formic to benzoic, chloroacetic, and salicylic acid, and simple aliphatic propanol and butanol chains. Each variation tunes lipophilicity, hydrogen-bonding capacity, and steric profile in a different way, allowing the team to read out structure-activity relationships directly from the docking results.

Before any docking was attempted, the compounds had to pass basic drug-likeness filters. Using the SwissADME web platform, the researchers confirmed that every derivative satisfied Lipinski’s Rule of Five and Veber’s oral bioavailability criteria without a single violation. Molecular weights ranged from 279.29 to 385.42 daltons, comfortably below the 500-dalton ceiling, while calculated LogP values between 1.02 and 3.72 suggested a workable balance between membrane permeability and aqueous solubility. Topological polar surface area values of 46.92 to 84.22 square angstroms and rotatable bond counts of five to seven fell within Veber’s limits, predicting efficient passive diffusion across the gut wall. In short, all eleven molecules looked like plausible oral drugs on paper.

Safety screening came next, using ProTox-III, a machine-learning platform trained on curated toxicological datasets. Predicted acute oral LD50 values ranged from 500 to 2000 milligrams per kilogram, placing every compound in GHS Toxicity Class IV, a category comparable to many approved pharmaceuticals. Human intestinal absorption was predicted to exceed 80 percent for the entire series, and carcinogenicity and mutagenicity predictions were negative for nearly all derivatives. Notably, low predicted blood-brain barrier penetration for most compounds hints at a peripherally acting antihistamine with reduced sedation risk, the defining drawback of first-generation H1 antagonists. One caution did emerge: SP7 and SP8 showed moderate predicted cardiotoxicity, a signal the authors stress must be verified with hERG channel assays, since cardiac liability contributed to the market withdrawal of some earlier COX-2 inhibitors.

The docking results were where the study delivered its headline findings. Using Schrödinger’s Glide Extra Precision protocol against human COX-2, the crystal structure of which was solved bound to ibuprofen, the team found that SP2, a resorcinol derivative, scored minus 8.032 kilocalories per mole and SP8, a salicylic acid derivative, scored minus 9.566 kilocalories per mole, both far ahead of ibuprofen’s benchmark of minus 5.779. The protocol was validated by re-docking the co-crystallized ligands, yielding root-mean-square deviations of 1.83 and 1.78 angstroms for COX-2 and the H1 receptor respectively, both under the accepted 2.0-angstrom threshold. SP8’s strength appears to come from its ortho-hydroxyl and carboxylate groups working in concert: the carboxylate forms a salt bridge with Arg120 while hydrogen bonds anchor to Tyr355 and Ser530, and hydrophobic packing into the enzyme’s channel stabilizes the complex.

Against the histamine H1 receptor, solved by cryo-electron microscopy in complex with desloratadine, the top performers were SP2 at minus 8.021 and SP11, a butanol-bearing derivative, at minus 8.627 kilocalories per mole, both surpassing the reference antihistamine astemizole at minus 6.519. These compounds engage the orthosteric binding pocket through hydrogen bonds with Asp107, Tyr108, Ser111, and Asn198, complemented by aromatic stacking against Trp428, Tyr431, and Phe432. The extended butyl chain of SP11 appears to fill hydrophobic sub-pockets lined by Phe432, Phe435, and Trp428, consistent with established structure-activity rules for lipophilic H1 ligands. Intriguingly, the SAR analysis suggested that lengthening the alkyl chain preferentially boosts H1 affinity over COX-2 affinity, giving medicinal chemists a tunable dial for target balance.

When docking affinity, drug-likeness, and predicted safety were weighed together, three compounds rose to the top for different reasons. SP2 shows the most balanced dual-target engagement, with its COX-2 and H1 docking scores within 0.1 kilocalories per mole of each other. SP8 is the strongest single COX-2 binder of the series, and SP11 the strongest H1 binder. A fourth compound, SP9, showed promising H1-selective trends thanks to a methoxy group that occupies a hydrophobic sub-pocket absent from COX-2, but its overall dual-target and safety profile did not outperform the three leads, so it was not carried forward. The authors are careful to note that GlideScores are empirical rankings, not thermodynamic binding free energies, and cannot substitute for measured inhibition constants.

That caveat frames the study’s honest limitations. Static docking cannot capture protein flexibility or induced-fit effects, and machine-learning ADMET models can be unreliable for chemotypes poorly represented in their training data. The authors recommend a clear experimental roadmap: synthesize SP2, SP8, and SP11; run in vitro COX-2 inhibition and H1 receptor binding assays; establish COX-1/COX-2 selectivity to gauge gastrointestinal risk; complete full experimental ADMET profiling including hERG testing; and then move to in vivo efficacy studies in inflammation and anaphylaxis models, with molecular dynamics simulations guiding further optimization. Until those experiments are done, the dual-acting promise of these molecules remains a well-supported hypothesis rather than a demonstrated therapy. Still, as a rational, hypothesis-generating screen, the work offers a concrete starting point for a next generation of medicines aimed at the frequent clinical overlap between allergy and inflammation.

Subject of Research: Computational evaluation of novel benzimidazole derivatives as dual COX-2 inhibitors and histamine H1 receptor antagonists

Article Title: Integrated computational evaluation of novel benzimidazole scaffolds as dual COX-2 inhibitory and histamine H1 antagonistic activity

Article References: Pawar, S., & Panzade, P. (2026). Integrated computational evaluation of novel benzimidazole scaffolds as dual COX-2 inhibitory and histamine H1 antagonistic activity. Discover Chemistry, 3(1), Article 566. https://doi.org/10.1007/s44371-026-01024-6

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01024-6

Keywords: benzimidazole, COX-2 inhibition, histamine H1 receptor, molecular docking, drug-likeness, ADMET prediction, SwissADME, ProTox-III, Glide XP docking, structure-activity relationship, computer-aided drug design, dual-target therapeutics

Halophytes occupy one of the most punishing niches in the plant world. Rooted in soils saturated with salt and repeatedly exposed to tidal flooding, intense sunlight and oxidative stress, they must defend themselves with an unusually robust chemical arsenal. That stress-driven metabolism often leads to elevated production of phenolics, flavonoids, tannins and other secondary metabolites, many of which have documented antioxidant, anti-inflammatory and even anticancer properties when tested in laboratory systems. Plants that manufacture these compounds to survive are, in effect, pre-formulating drugs, and the Bharathidasan team set out to quantify exactly how much pharmacological value two representative species carry.

The researchers collected both plants from the Cuddalore coast region of Tamil Nadu and prepared a series of solvent extracts, ranging from non-polar hexane to more polar ethyl acetate and other fractions. Sequential extraction with solvents of increasing polarity is a standard strategy in natural products chemistry because different classes of compounds partition differently: non-polar solvents pull out lipids, terpenoids and certain phenolic derivatives, while more polar solvents recover flavonoid glycosides, tannins and free amino acids. By comparing the same plant across solvents, the team could pinpoint which fraction carried which activity, a critical step for anyone hoping to isolate a single therapeutic molecule later.

The chemical inventory was striking. The ethyl acetate extract of Suaeda maritima recorded the highest total flavonoid content at 272.74 milligrams of quercetin equivalents per gram, alongside 114.32 milligrams of gallic acid equivalents per gram of total phenolics, 95.68 milligrams of tannic acid equivalents per gram of tannins, and 122.43 milligrams of leucine equivalents per gram of free amino acids. These are substantial concentrations for a wild-harvested marsh plant. Flavonoids and phenolic acids are the classical workhorses of plant antioxidant chemistry, capable of donating electrons or hydrogen atoms to neutralise reactive oxygen species, the unstable molecules implicated in inflammation, cardiovascular disease, neurodegeneration and cancer progression.

Bioactivity testing told an equally interesting story, but with a twist in which plant came out ahead. The hexane extract of Sesuvium portulacastrum delivered the strongest radical-scavenging performance in the DPPH assay, with an IC50 value of 63.32 micrograms per millilitre, meaning the concentration needed to neutralise half of the synthetic free radicals in the test. The same hexane fraction also dominated the anti-inflammatory battery of tests: it inhibited heat-induced denaturation of bovine serum albumin with an IC50 of 68.18 micrograms per millilitre, suppressed proteinase activity with an IC50 of 66.21 micrograms per millilitre, and scavenged nitric oxide with an IC50 of 58.65 micrograms per millilitre. Protein denaturation is a hallmark of inflammatory states, and compounds that stabilise protein structure or block proteolytic enzymes are considered useful templates for anti-inflammatory drug development. Nitric oxide, while a vital signalling molecule at physiological levels, becomes a damaging inflammatory mediator when overproduced, so nitric oxide scavenging is another clinically relevant benchmark.

The observation that non-polar hexane fractions produced the strongest functional effects, while polar ethyl acetate fractions carried the highest measured phytochemical content, illustrates a recurring lesson in pharmacognosy: quantity of known marker compounds does not always predict biological potency. Hexane-soluble constituents such as fatty acid derivatives, terpenoids and certain lipophilic phenolics can be disproportionately active even when classical colorimetric assays register their presence weakly. Identifying which specific molecules drive the activity requires chemical characterisation at the compound level, and this is where the team turned to instrumental analysis.

Gas chromatography coupled with mass spectrometry, or GC–MS, was used to profile the volatile and semi-volatile constituents of the extracts, revealing a suite of major bioactive compounds characteristic of halophyte chemistry. To prioritise candidates for drug development, the researchers then turned to molecular docking, a computational technique that predicts how tightly a small molecule fits into the binding pocket of a disease-relevant protein. Two inflammatory protein structures, deposited in the Protein Data Bank under the identifiers 1IK3 and 5IKR, served as the molecular targets. Among the identified phytochemicals, 7,9-di-tert-butyl-1-oxaspiro(4,5)deca-6,9-diene-2,8-dione showed the strongest binding affinities, at minus 7.1 and minus 7.0 kilocalories per mole for the two targets respectively. Binding energies in this range suggest meaningful intermolecular contacts such as hydrogen bonding and hydrophobic packing, which in docking studies are typically taken as an encouraging, though preliminary, sign of inhibitory potential.

The team also ran the lead compounds through SwissADME, a widely used web platform that estimates whether a molecule behaves like a plausible oral drug. The analysis indicated favourable drug-like properties, including profiles consistent with reasonable absorption, distribution and metabolic behaviour under the standard Lipinski-style criteria used in early drug discovery. No docking study or ADME prediction can replace experimental pharmacology, but together they act as a molecular sieve, filtering dozens of crude extract constituents down to a shortlist of compounds worth the expense of isolation, synthesis and biological testing.

The authors are careful to frame the work as an early-stage screening effort rather than a therapeutic claim. All of the antioxidant and anti-inflammatory data come from in vitro assays, and the docking results are computational predictions; the study itself concludes that the halophytes, particularly their hexane extracts, warrant further in vitro and in vivo investigation. That pipeline matters: many plant extracts that shine in a test tube fail when confronted with living systems, where issues of bioavailability, metabolism, toxicity and target specificity intervene. Nevertheless, the convergence of strong assay results, identifiable bioactive compounds, encouraging docking scores and favourable drug-likeness predictions is exactly the combination that natural products chemists look for when deciding which species to pursue.

Beyond the laboratory, the study carries an ecological and economic message. Coastal salt marshes are often treated as wastelands, reclaimed for aquaculture, industry or development, yet they harbour species with demonstrated pharmaceutical value and play vital roles in shoreline protection and nutrient cycling. Work of this kind strengthens the case for conserving these habitats, both for their ecosystem services and as living libraries of chemical diversity. If subsequent animal studies and, eventually, clinical research confirm the promise suggested by the Cuddalore samples, the humble marsh plants swaying at the edge of the Bay of Bengal may find a second career as sources of next-generation anti-inflammatory medicines.

Subject of Research: Antioxidant and anti-inflammatory bioactive compounds in coastal halophyte plants

Article Title: Assessment of antioxidant and anti-inflammatory effects of Suaeda maritima and Sesuvium portulacastrum collected from Cuddalore coast region

Article References: Baskaran, G., Natesan, M., Palanisamy, B. M., Mathiyazhagan, S., & Raji, S. (2026). Assessment of antioxidant and anti-inflammatory effects of Suaeda maritima and Sesuvium portulacastrum collected from Cuddalore coast region. Plant Biosystems, 160(5), Article 254. https://doi.org/10.1007/s44473-026-00266-7

Image Credits: AI Generated

DOI: 10.1007/s44473-026-00266-7

Keywords: halophytes, Suaeda maritima, Sesuvium portulacastrum, antioxidant activity, anti-inflammatory, phytochemistry, molecular docking, GC-MS, SwissADME, salt marsh, natural products, Cuddalore coast